The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Requirement of activation of complement C3 and C5 for antiphospholipid antibody–mediated thrombophilia
Open accessAbstract
Objective: Antiphospholipid antibodies (aPL) have been shown to induce thrombosis, activate endothelial cells, and induce fetal loss. The pathogenesis of aPL‐induced thrombosis, although not completely understood, may involve platelet and endothelial cell activation as well as procoagulant effects of aPL directly on clotting pathway components. Recent studies have shown that uncontrolled complement activation leads to fetal death in aPL‐treated mice. In this study, we tested the hypothesis that aPL are responsible for activation of complement, thus generating split products that induce thrombosis. Methods: To study thrombus dynamics and adhesion of leukocytes we used in vivo murine models of thrombosis and microcirculation, in which injections of aPL were used. Results: Mice deficient in complement components C3 and C5 were resistant to the enhanced thrombosis and endothelial cell activation that was induced by aPL. Furthermore, inhibition of C5 activation using anti‐C5 monoclonal antibodies prevented thrombophilia induced by aPL. Conclusion: These data show that complement activation mediates 2 important effectors of aPL, induction of thrombosis and activation of endothelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simplification of the protein assay method of Lowry et al. which is more generally applicable
Peterson, G. L. (1977) · Analytical Biochemistry · doi:10.1016/0003-2697(77)90043-4 · Cited by 8,524
Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation
Girardi, G., Redecha, P., & Salmon, J. E. (2004) · Nature Medicine · doi:10.1038/nm1121 · Cited by 680
Self-citationHillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031688 · Cited by 635
Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal Loss
Holers, V. M., Girardi, G., Mo, L., Guthridge, J. M., Molina, H., Pierangeli, S. S., Espinola, R., Xiaowei, L. E., Mao, D., Vialpando, C. G., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.200116116 · Cited by 626
Self-citationComplement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318817 · Cited by 594
Self-citationComplement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18817 · Cited by 575
Self-citationWang, Y., Rollins, S. A., Madri, J. A., & Matis, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8955 · Cited by 360
Wang, Y., Hu, Q., Madri, J. A., Rollins, S. A., Chodera, A., & Matis, L. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8563 · Cited by 336
Pierangeli, S. S., Colden-Stanfield, M., Liu, X., Barker, J. H., Anderson, G. L., & Harris, E. N. (1999) · Circulation · doi:10.1161/01.cir.99.15.1997 · Cited by 325
Self-citationMembrane attack by complement: the assembly and biology of terminal complement complexes
Tegla, C. A., Cudrici, C., Patel, S., Trippe, R., Rus, V., Niculescu, F., & Rus, H. (2011) · Immunologic Research · doi:10.1007/s12026-011-8239-5 · Cited by 321
Cited by
Ruiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Dimitriadis, E., Menkhorst, E., Saito, S., Kutteh, W. H., & Brosens, J. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00228-z · Cited by 702
The Pathogenesis of the Antiphospholipid Syndrome
Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 688
Pathogenesis of antiphospholipid syndrome: understanding the antibodies
Meroni, P. L., Borghi, M. O., Raschi, E., & Tedesco, F. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.52 · Cited by 620
“This conclusion is supported by the finding that animals deficient in complement components or complement receptors, or treated with inhibitors of complement activation, were protected from the thrombogenic effect of aPL”
ResultEndothelium structure and function in kidney health and disease
Jourde-Chiche, N., Fakhouri, F., Dou, L., Bellien, J., Burtey, S., Frimat, M., Jarrot, P.-A., Kaplanski, G., Le Quintrec, M., Pernin, V., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0098-z · Cited by 493
Ritis, K., Doumas, M., Mastellos, D., Micheli, A., Giaglis, S., Magotti, P., Rafail, S., Kartalis, G., Sideras, P., & Lambris, J. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4794 · Cited by 489
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 265
McNamee, K. M., Dawood, F., & Farquharson, R. G. (2014) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2013.10.007 · Cited by 125
Coughlin, B., Schnabolk, G., Joseph, K., Raikwar, H., Kunchithapautham, K., Johnson, K., Moore, K., Wang, Y., & Rohrer, B. (2016) · Scientific Reports · doi:10.1038/srep23794 · Cited by 65
Antiphospholipid syndrome: an update for clinicians and scientists
Vreede, A. P., Bockenstedt, P. L., & Knight, J. S. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000410 · Cited by 22
Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome
Petri, M. (2019) · Hematology · doi:10.1182/hematology.2019000046 · Cited by 11
Metadata
- Authors
- Pierangeli, S. S., Girardi, G., Vega‐Ostertag, M., Liu, X., Espinola, R. G., & Salmon, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-06-28
- Volume
- 52
- Issue
- 7
- Pages
- 2120-2124
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2008273918
- Cited by
- 362
- References
- 20
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.